Scarica l'app Stockscreener
119.78
0.51%
-0.62
Pre-mercato:
120.00
0.22
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead’s experimental HIV treatment meets main goal in late-stage trial - WKZO
Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial - Reuters
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial - European AIDS Treatment Group
Gilead to start demolishing buildings for campus expansion by end of month - The Business Journals
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains - Investing.com
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal - Benzinga
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meet - pharmiweb.com
Wolfe Research Adjusts Gilead Sciences PT to $150 From $140, Maintains Outperform Rating - marketscreener.com
Gilead Sciences Reports Positive Phase 3 ARTISTRY-2 HIV Trial Results - Nasdaq
Gilead (GILD) Hits Key Milestone with ARTISTRY-2 HIV Treatment T - GuruFocus
Gilead Yeztugo HIV combo pill meets goal in second phase 3 trial - Seeking Alpha
Gilead reports positive results for HIV treatment combination By Investing.com - Investing.com South Africa
Gilead Sciences, Inc. $GILD Shares Bought by Westwood Holdings Group Inc. - MarketBeat
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Orion Porfolio Solutions LLC - MarketBeat
Gilead Sciences stock price target raised to $150 from $140 at Wolfe Research - Investing.com
Pitcairn Co. Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Kestra Investment Management LLC Acquires 9,551 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
National Bank of Canada FI Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Farmers Trust Co. Sells 11,071 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
MASTERINVEST Kapitalanlage GmbH Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Thrivent Financial for Lutherans Sells 238,111 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stance Capital LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Trimmed by China Universal Asset Management Co. Ltd. - MarketBeat
Continental Advisors LLC Sells 9,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stock Traders Buy Large Volume of Gilead Sciences Call Options (NASDAQ:GILD) - MarketBeat
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)? - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - MarketBeat
Treasurer of the State of North Carolina Has $85.51 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc. - MarketBeat
BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - MarketBeat
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - 1470 & 100.3 WMBD
Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Main - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Arcus scraps late-stage cancer trial after weak survival data - Reuters
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
HUB Investment Partners LLC Has $5.49 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Oncodaily
Ex-Dividend Reminder: Gilead Sciences, Merck and Horace Mann Educators - Nasdaq
January 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades - TIKR.com
CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc. - MarketBeat
Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend - simplywall.st
2.24%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):